Plasma Tumor Mutation Burden and Response to Pembrolizumab-Letter
Clin Cancer Res
.
2021 Mar 1;27(5):1580.
doi: 10.1158/1078-0432.CCR-20-2698.
Authors
Zhiqiang Xue
#
1
,
Xueguang Guo
#
2
,
Jiaxin Wen
3
,
Wenhan Cai
3
,
Xinying Xue
4
,
Xiaochen Zhao
5
,
Jing Zhao
5
,
Yuezong Bai
5
Affiliations
1
Department of Thoracic Surgery, The First Medical Center of Chinese PLA General Hospital, Beijing, P.R. China. xuezhiqiang301@126.com.
2
Department of Medical Oncology, The Second Medical Center of PLA General Hospital, Beijing, P.R. China.
3
Department of Thoracic Surgery, The First Medical Center of Chinese PLA General Hospital, Beijing, P.R. China.
4
Department of Respiratory and Critical Care, Beijing Shijitan Hospital, Capital Medical University, Beijing, P.R. China.
5
The Medical Department, 3D Medicines Inc., Shanghai, P.R. China.
#
Contributed equally.
PMID:
33649190
DOI:
10.1158/1078-0432.CCR-20-2698
No abstract available
Publication types
Letter
Comment
MeSH terms
Antibodies, Monoclonal, Humanized
Carcinoma, Non-Small-Cell Lung*
Humans
Lung Neoplasms*
Mutation
Substances
Antibodies, Monoclonal, Humanized
pembrolizumab